Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors.
- 1 May 1994
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation
- Vol. 89 (5) , 2232-2240
- https://doi.org/10.1161/01.cir.89.5.2232
Abstract
BACKGROUND: To elucidate the extent of the compensatory role of endogenous atrial natriuretic peptide (ANP) in severe congestive heart failure (CHF), we examined the changes in hemodynamics and neuroendocrine and renal functions after incremental administration of an ANP antagonist, HS-142-1 (HS), in dogs with CHF. METHODS AND RESULTS: We assessed the effects of HS on the suppression of plasma and urinary cGMP levels as a marker of endogenous ANP activity in dogs without CHF. Bolus injections of 0.3 and 1.0 mg/kg HS reduced plasma cGMP levels to 77% and 60% and urinary cGMP excretion to 78% and 61% of the relevant control levels, respectively. Then the study was performed in dogs with CHF induced by chronic rapid ventricular pacing, and the plasma ANP level was sixfold higher than that in the controls. Hemodynamic, hormonal, and renal variables were determined both before and after subsequent incremental administration (0.3, 1.0, and 3.0 mg/kg every 30 minutes) of HS. HS lowered the plasma and urinary cGMP levels dose dependently to 32% and 37% of the control levels, respectively. Mean arterial, pulmonary capillary wedge, and right atrial pressures and cardiac output did not change significantly. However, plasma renin activity, aldosterone level, and norepinephrine level increased rapidly to 226%, 179%, and 252% of the control values, respectively. Urine flow rate and urinary sodium excretion were significantly inhibited, with no concomitant change in glomerular filtration rate or renal plasma flow. CONCLUSIONS: These findings suggest that endogenous ANP contributes to the suppression of the activation of the renin-aldosterone system and sympathetic nervous activity and body fluid retention but that the vasodilative action of this peptide is attenuated in advanced CHF.Keywords
This publication has 38 references indexed in Scilit:
- Lysosomal delivery of ANP receptors following internalization in PC12 cellLife Sciences, 1993
- HS-142-1, a novel antagonist for natriuretic peptides, has no effect on the third member of membrane bound guanylate cyclases (GC-C) in T84 cellsLife Sciences, 1993
- Stable expression of natriuretic peptide receptors: Effects of HS-142-1, a non-peptide ANP antagonistBiochemical and Biophysical Research Communications, 1992
- Cloning and characterization of two froms of C-type natriuretic peptide receptor in rat brainBiochemical and Biophysical Research Communications, 1992
- Effects of HS-142-1, a novel non-peptide ANP antagonist, on diuresis and natriuresis induced by acute volume expansion in anesthetized ratsBiochemical and Biophysical Research Communications, 1992
- Effects of amino acid infusion on renal hemodynamics. Role of endothelium-derived relaxing factor.Hypertension, 1991
- Microbial polysaccharide, HS-142-1, competitively and selectively inhibits ANP binding to its guanylyl cyclase-containing receptorBiochemical and Biophysical Research Communications, 1991
- Hemodynamic, Renal, and Hormonal Effects of 8-Br-Cyclic GMP in Conscious Dogs With and Without Congestive Heart FailureJournal of Cardiovascular Pharmacology, 1989
- Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failureAmerican Heart Journal, 1989
- Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.Hypertension, 1987